UCLA’s $5,000 T-Cell Therapy Could Upend Solid-Tumor Cancer Treatment

Key Points:

• UCLA researchers have developed AlloESO-T cells, an off-the-shelf engineered T-cell therapy derived from donated cord blood, targeting solid tumors such as ovarian cancer, melanoma, and prostate cancer, with an estimated cost of around $5,000 per dose compared to hundreds of thousands for current autologous therapies.
• Unlike CAR-T therapies that target proteins on the cancer cell surface, AlloESO-T cells use TCR therapy to recognize internal tumor proteins presented via HLA molecules, specifically targeting the NY-ESO-1 antigen common in several solid tumors.
• The platform incorporates four key engineering innovations, including engineering TCRs at the stem-cell stage to prevent graft-versus-host disease and adding NK cell receptors to counter tumor antigen escape, demonstrating strong tumor targeting and safety in mouse models.
• This approach aims to create a scalable manufacturing system that can be adapted to different tumor antigens by swapping TCRs, potentially transforming cell therapy into an off-the-shelf product with significantly reduced costs and broader accessibility.
• While promising preclinical results show efficacy and safety in mice, AlloESO-T cells have not yet entered human trials or received FDA approval, and further clinical testing is needed to confirm their potential for treating solid tumors in patients.